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Abstract
Background: To evaluate the efficacy of an intravitreal dexamethasone (IVD) implant (Ozurdex®) for the treatment
of central retinal vein occlusion (CRVO) without macular edema (ME).
Methods: A retrospective cohort study was designed, and 20 eyes of 20 patients diagnosed with non-ischemic
CRVO without ME were included. A total of 10 CRVO eyes were observed without treatment, and another 10 CRVO
eyes received a single IVD injection at baseline. Mean changes in pathomorphologic parameters of fundus and
optical coherence tomography parameters were measured at baseline and at 1, 3, 6, and 12 months.
Results: The decreases in venous tortuosity (p = 0.014 for superior; 0.036 for inferior arcades) and width (p = 0.024
for superior; 0.003 for inferior arcades) from baseline to 12 months after injection were significantly greater in the
treated group than the observed group. The improvements in RNFL swelling (p = 0.010) and retinal hemorrhage
(p = 0.006) were also significantly greater in the treated group. Visual symptom improvement was significantly faster in
the treated group (p = 0.001). In two cases, IVD injection resulted in complete resolution of cilioretinal artery occlusion
associated with the CRVO, leading to complete visual recovery in 1 week. None of the treated eyes showed signs of
ME development, ischemia progression, or neovascularization.
Conclusions: IVD implant was significantly effective in improving venous engorgement, retinal hemorrhage, RNFL
swelling, and visual symptoms by presumed alleviation of disc swelling and venous outflow. This treatment may be a
considerable treatment option in CRVO patients with no ME.
Keywords: Central retinal vein occlusion, Intravitreal dexamethasone implant, Ozurdex, Steroid, Fundus
pathomorphology
Background
Central retinal vein occlusion (CRVO) is caused by a
venous outflow blockage in the main trunk of the central
retinal vein. It can result in severe vision loss due to
macular edema (ME), intraretinal hemorrhage, and is-
chemia leading to neovascularization [1–3]. Unlike
branch retinal vein occlusion, the precise CRVO block-
age site cannot be easily seen in the retina, as it is
thought to occur within the optic nerve. The etiology of
CRVO is not clearly known, and is thought to result
from a combination of multiple factors. CRVO in elderly
individuals may be due to abnormally increased arterial
stiffness affecting neighboring veins [4, 5]. Some have
concluded that the compact anatomy of optic nerve
head (ONH) may play a role in the pathogenesis of
CRVO [6–8]. Additionally, inflammation of the central
retinal or peripapillary vein has been proposed as a pos-
sible cause, especially in young adults [9, 10].
The prognosis of CRVO can differ depending on its
angiographic subtype: either ischemic or non-ischemic,
and the primary cause of poor visual outcome in ische-
mic CRVO is ME [11]. Natural clinical courses of the
two CRVO types are completely different: outcome is
much better in non-ischemic CRVO than in ischemic
CRVO. However, more than 2/3 of non-ischemic CRVO
patients showed vision and visual field deterioration at
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their 3-month follow-up assessment [12]. Resolution of
retinal venous engorgement was seen within only 1 year
in 17.3% of non-ischemic CRVO with or without ME
[13]. Optic disc edema also remained in approximately
20% of cases, even after 24 months [13]. Moreover, the
Central Vein Occlusion Study (CVOS) [14] reported that
although over 75% of CRVOs are non-ischemic, 34% of
those cases converted to the ischemic form during
3-year follow-up. In the CVOS study [2], up to 60% of
eyes with ischemic CRVO developed neovascularization,
usually in the anterior segment, with neovascular glau-
coma developing in one-third of all ischemic CRVO
cases.
In the treatment of CRVO with ME, the GENEVA
study [15] revealed that intravitreal steroid therapy could
significantly improve ME and visual outcomes. However,
for CRVO patients without ME complaining of severely
decreased visual quality or newly developed blind spots,
there is no currently recommended treatment available
for now. Frequent follow-up is the only recommenda-
tion, which monitors the development of ME, neovascu-
larization, and conversion to ischemic CRVO, which can
cause serious impairments to the patient’s visual out-
comes. Edematous change of ONH associated with un-
known inflammatory reaction leading to compression of
CRV have been suggested as possible causes of CRVO
[9, 16]. Therefore, use of intravitreal steroids as a pos-
sible treatment could be considered due to the inflam-
matory pathogenic mechanism of CRVO, even in eyes
without ME [17, 18]; however, there has been no clinical
study investigating the efficacy of intravitreal steroid treat-
ment in CRVO eyes with no ME. We hypothesize that in-
travitreal dexamethasone (IVD) implant (Ozurdex®;
Allergan Inc., Irvine, CA, USA) treatment will act to re-
lieve ONH swelling by providing an anti-inflammatory ef-
fect, thereby alleviating central venous outflow. Therefore,
we retrospectively compared clinical outcomes between
IVD-injected and untreated patients to investigate the po-
tential therapeutic effect of IVD implant in CRVO without
ME.
Methods
Study design and participants
We designed a retrospective cohort study to evaluate the
anatomical and functional effectiveness of IVD implant
treatment in CRVO eyes. This study was carried out at a
single center – Gangnam Severance Hospital, Seoul,
Korea - by two retina specialists (E.Y.C, M.K.). Study sub-
jects were collected through a review of medical records
from February 2012 to April 2017. This study was ap-
proved by the Institutional Review Board at Gangnam
Severance Hospital (IRB approval number: 3–2017-0112).
We did not obtain patient consent, since data were ana-
lyzed anonymously. Only patients with definitive diagnosis
of non-ischemic CRVO without ME were included in this
study. CRVO patients with signs of inner retinal ischemia
(e.g., ocular neovascularization, 10 disc areas or more of
retinal capillary non-perfusion, or relative afferent
pupillary defect) were excluded. We excluded patients
who had been treated by intravitreal drug injections or
laser photocoagulation before the baseline study. Patients
with other retinal disorders (e.g., diabetic retinopathy or
age-related macular degeneration), optic nerve diseases
(e.g., optic neuritis, glaucoma, or ischemic optic neur-
opathy), or uveitis were also excluded.
We reviewed the medical records of 29 eligible pa-
tients who had non-ischemic CRVO but no ME. Nine
cases were excluded from the analysis due to incomplete
data. One-year follow-up was not completed in four
cases. In the other five cases, some of the tests required
for analysis were not performed. Ozurdex® was approved
by the Korea Ministry of Food and Drug Safety in No-
vember 2011 for the treatment of ME following retinal
vein occlusion, and it was actually applied in 2013 by
our institution. IVD implant therapy was administered
to all CRVO without ME patients who agreed to treat-
ment since January 2013, except for two patients who
refused treatment. Before that time, CRVO eyes with no
ME were usually observed without any treatment. There
were no additionally required conditions regarding the
decision to treat.
Patients were divided into the following two groups
according to their treatment history for comparative
analysis: untreated observation group and IVD
implant-treated group. Treatment history of each patient
was unknown to the study investigators who collected
patient data and assessed outcomes.
The observation group patients were followed up with-
out any treatment, and the IVD-treated group patients
received a single injection within 1 week after the onset
of symptoms. Every IVD implantation was performed by
a single retina specialist (M.K.) following the routine in-
jection protocol: topical anesthesia (0.5% proparacaine)
was applied and 5% betadine solution was placed into
inferior fornix after lid scrub with povidone-iodine.
Sustained-release dexamethasone (Ozurdex®) (0.70 mg)
was administrated 3.0–3.5 mm posterior to limbus
through the pars plana using a sterile technique.
Study outcomes
The primary outcome was the mean changes in patho-
morphologic parameters of the fundus (such as vessel
tortuosity, central retinal vein width, retinal hemorrhage
amount, and cotton wool spots), and spectral-domain
optical coherence tomography (SD-OCT) parameters
(such as central macular thickness, subfoveal choroidal
thickness, and retinal nerve fiber layer [RNFL] thickness
of the optic nerve head). For secondary outcomes, we
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compared the final visual acuity and the time point
when visual symptoms had improved.
The results of ophthalmic evaluations were collected
at the initial visit and at follow-up times of 1 month, 3
months, 6 months, and 12months after either the initial
visit or IVD treatment. The collected data included
best-corrected visual acuity (BCVA, logMAR) and intra-
ocular pressure (IOP, mmHg), results of detailed anterior
segment and fundus examinations, fundus photography,
wide field fundus imaging, SD-OCT, and fluorescein
fundus angiography. Whether the patient’s visual symp-
tom had improved or not was also evaluated. Fundus
photography, fluorescein angiography, and wide-field
fundus imaging each captured images of 30°, 55°, and
200° of the retina. SD-OCT images were obtained with
Heidelberg SD-OCT (Spectralis®; Heidelberg Engineer-
ing, Heidelberg, Germany), and included enhanced
depth imaging to evaluate the deep choroid layers. Both
fundus photography and wide field fundus images were
used for the analysis of central retinal veins (CRV), pres-
ence of retinal hemorrhage, and cotton wool spots. Ves-
sel tortuosity of superior and inferior CRV was
measured as the relative length variation, defined as the
integral of curvature normalized by the total path length
using the formula shown in Fig. 1 [19–21]. Vascular ana-
lysis was limited to within the extent visible in the cen-
tral retina (approximately 6 mm around the fovea).
Vessel length was measured using ImageJ software (Ver-
sion 1.47, NIH, Maryland, USA). Vessel widths of super-
ior and inferior CRV were measured using the diameter
plug-in of ImageJ software, which was the average of
three points: at the disc margin, at 1.0 disc diameters
(DD), and at 2.0 DDs from the margin (Fig. 1). Retinal
hemorrhage was subjectively graded as 0 = no hemor-
rhages, 1 =minimal/small hemorrhages, 2 =medium
amount of hemorrhages, or 3 = extensive hemorrhages
in six divided fundus regions: the macular region,
remaining posterior pole, and peripheral region divided
into four sub-areas. [13] The sum of the weighted
hemorrhage scores was calculated using the following:
grade × 10 in the macular region, × 5 in the rest of pos-
terior pole, and × 1 in a quarter of the peripheral region.
Cotton wool spots were evaluated by the total number
in the central retina.
Superior and inferior RNFL thickness of ONH were
measured automatically by the built-in software
(HEYEX PACS™ Version 1.8) of Heidelberg OCT
viewer. Thickness of the central macula was measured
automatically, and choroidal thickness was measured
manually by using the caliper tool provided by the
same software, measuring the distance from the ret-
inal pigment epithelium to the chorioscleral junction
at the subfoveal center. All tests and measurements
were performed by two masked observers (E.Y.C,
H.G.K.). The averaged values of the results obtained
by two masked observers were used for analysis. No
measurement was excluded due to a serious discrep-
ancy between the two observers.
Fig. 1 Illustration of the subdivision used to estimate vessel
tortuosity (a) and vascular width (b). Magnified (3×) fundus photo
images were used for the analysis, and images showing the
subdivided superior central retinal vein are presented. With imageJ
software (Version 1.47, NIH, Maryland, USA), image was processed
twice: sharpening to enhance the vessel cords for tortuosity analysis
(a) and reversal to highlight the vessel walls for width analysis (b).
Vessel tortuosity was estimated with relative length variation (refer
to equation of top) by using straight and freehand line selection
tools (a). Vascular width was measured at three points: at disc
margin at 1.0 disc diameter from the margin, and at 2.0 disc
diameter from the margin by using straight line selection tool (b).
L = curvilinear length of the vessel; l = linear length of the chord;
vw = vascular width
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Sample size and statistical analysis
Since the prevalence of CRVO was low (< 0.1 to 0.3%)
[3, 22–24] and this study was conducted as an explora-
tory study to investigate the therapeutic effect of IVD
implant only in CRVO eyes without ME, the number of
subjects was determined as the minimum. Therefore, by
using the decision-theoretic approach, the estimated
sample size was 9, with a relatively high assumed mean
response rate for IVD treatment, 0.85 and with low prior
weight, 2.
A Bland-Altman assessment was used to assess the
agreement of the measurements by two observers. A
range of agreement was defined as mean bias ±2 standard
deviation [25]. There was no measurement which showed
a clinically important discrepancy. The averaged values of
the results obtained by two masked observers were used
for the analysis. Means ± standard deviations are pre-
sented for continuous variables, and Mann-Whitney U
test was used to compare the groups at each time point.
Fisher’s exact test was used for categorized parameters,
which are expressed as frequencies. Changes in continu-
ous variables between baseline and endpoints were ana-
lyzed using Wilcoxon signed rank test. The impact of IVD
implant injection on the course of pathomorphological
changes in the fundus was analyzed by the generalized es-
timating equation according to the data distribution pat-
tern. SPSS software (version 23.0, SPSS, Inc.) was used for
statistical analysis. A p-value less than 0.05 was considered
statistically significant. All statistical tests were two-sided
at the 95% confidence interval.
Results
Ten observed CRVO eyes and another 10 IVD-treated
CRVO eyes were analyzed in each group and compared
to each other. All subjects were followed up for at least
1 year. There were no injection-related serious adverse
events reported, including infection, glaucoma, and cata-
racts. Table 1 shows the baseline characteristics of the
patients at the first visit or prior to the first IVD implant
treatment. There were no significant differences in age,
sex, BCVA, IOP, spherical equivalents, and the mean
time since onset of disease between the two groups. Sys-
temic diseases such as hypertension and type 2 diabetes
mellitus were found more frequently in the observation
group than in the IVD-treated group, but the difference
was not statistically significant. No patient had a history
of hypercoagulopathy or systemic autoimmune/inflam-
matory diseases.
In two patients, IVD injection resulted in complete
resolution of cilioretinal artery occlusion associated with
CRVO leading to complete visual recovery in 1 week.
The first patient was a young woman in her late 20s
(Fig. 2) who visited the emergency room because of sud-
den vision loss in her left eye. Her BCVA was 20/200,
and no remarkable sign was noted in the anterior seg-
ment and vitreous. Fundus examination revealed a cilior-
etinal artery occlusion and moderate vascular tortuosity
without any sign of ME. After 3 days, disc edema and
vascular tortuosity became worse and a dense retinal
hemorrhage appeared on the temporal side of the optic
disc. There was no change in her VA. IVD treatment
was performed on her left eye. A week later, her BCVA
dramatically improved to 20/28. Disc swelling and cilior-
etinal artery occlusion were improved at 1 month after
the injection, and her BCVA recovered to 20/20 at that
time. The other case (Fig. 2) was a patient in her late 30s
who visited our clinic due to an abrupt visual field defect
in her right eye. Her BCVA was 20/25. Fundus
Table 1 Baseline clinical characteristics of patients with central retinal vein occlusion without macular edema
Observation group IVD-treated group p-value
Patients/ eyes (N) 10/10 10/10 N/A
Sex, female/ maleb (N) 9/2 7/2 0.38
Involved eye, right/ leftb (N) 6/5 3/6 0.67
Mean agea (y) 51.7 ± 20.7 43.2 ± 12.2 0.15
Hypertensionb (N (%)) 3 (27.3) 1 (11.1) 0.36
Type 2 diabetesb (N (%)) 2 (18.2) 1 (11.1) 0.88
Hypercoagulopathy (N (%)) 0 (0) 0 (0) N/A
Systemic autoimmune/inflammation (N (%)) 0 (0) 0 (0) N/A
Mean BCVAa (logMAR) 0.11 ± 0.23 0.12 ± 0.33 0.61
Mean IOPa (mmHg) 14.3 ± 2.0 12.0 ± 3.2 0.44
Spherical equivalenta (diopter) −0.60 ± 0.53 −0.89 ± 0.34 0.27
Mean duration of the diseasea (weeks) 3.6 ± 4.6 3.8 ± 3.3 0.06
Values are presented as mean ± standard deviation
IVD intravitreal dexamethasone, BCVA best-corrected visual acuity, IOP intraocular pressure
aMann-Whitney U test and bFisher’s exact test were used for analysis
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examination revealed ischemic changes to the macular
area supplied by the cilioretinal artery; additionally, mul-
tiple blot hemorrhages were found throughout the retina
with tortuous retinal veins in her right eye. No other ab-
normal signs were observed. A week later, her BCVA
was unchanged; however, a markedly increased number
of retinal hemorrhages and cotton wool spots with se-
vere disc swelling were noted, although there was no
sign of ME. Her right eye was treated with IVD. Seven
days later, her BCVA was recovered to 20/20, and im-
provements in disc swelling and retinal hemorrhages
were noted. One month later, vascular tortuosity and
retinal hemorrhages improved dramatically with almost
complete resolution of cilioretinal artery occlusion and
disc swelling. In both CRVO cases, an extensive labora-
tory workup associated with systemic coagulopathy and
inflammatory/autoimmune conditions was performed,
and erythrocyte sedimentation rate (ESR) elevation was
confirmed.
Longitudinal changes of pathomorphological parameters
over a 1 year peroid
At baseline, fundus examinations revealed no significant
differences between the groups (Table 2, p = 0.78). Su-
perior vessel tortuosity significantly decreased from 0.34
± 0.20 at baseline to 0.17 ± 0.07 after 1 year in the
IVD-treated group (Table 2, p = 0.025), whereas patients
in observation group experienced no significant change
in superior vascular tortuosity measuring 0.24 ± 0.14 at
baseline and 0.18 ± 0.05 after 1 year (Table 2, p = 0.094).
Similarly, inferior vein tortuosity significantly decreased
from 0.67 ± 0.45 at baseline to 0.18 ± 0.13 at 1 year
(Table 2, p = 0.002) in the treated group, whereas in the
untreated CRVO eyes, inferior vessel tortuosity showed
no significant decrease within 1 year, from 0.50 ± 0.15 at
baseline to 0.33 ± 0.15 (Table 2, p = 0.059). Interestingly,
there was a statistical difference between the two groups
regarding superior and inferior vascular tortuosity de-
crease (p = 0.014 and 0.036) from baseline to the last visit.
Superior vascular width significantly decreased from
310.13 ± 79.89 μm at baseline to 245.03 ± 58.82 μm at 12
months in the IVD-treated group (Table 2, p = 0.007),
and from 297.28 ± 69.87 at baseline to 238.37 ± 70.56 at
12 months in the observation group (Table 2, p = 0.014).
Inferior vessel width also significantly decreased from
295.05 ± 88.79 μm at baseline to 213.20 ± 48.21 μm at 12
months in the treated group (Table 2, p = 0.001), but
showed no significant decrease from 285.30 ± 68.63 at
baseline to 227.01 ± 49.21 at 12 months in the observed
group (Table 2, p = 0.11). A significant difference was
found only at 1 month in both the superior and inferior
central vein width (p = 0.020 and 0.012, respectively).
The decrease from baseline to the last visit was signifi-
cantly larger in the treated group than in the
non-treated group for both superior and inferior vascu-
lar width (p = 0.024 and 0.003, respectively).
The grades of retinal hemorrhage significantly de-
creased from 27.70 ± 9.70 at baseline to 3.16 ± 4.88 at 12
Fig. 2 Representative figures at each time point of two cases of Ozurdex-treated central retinal vein occlusion (CRVO) eyes with cilioretinal artery
occlusion. A patient between the ages of 25 and 29 years (a) and a patient between the ages of 35 and 39 years (b) with CRVO and cilioretinal
artery occlusion in their left and right eye each. Disc swelling and cilioretinal artery occlusion were significantly improved at 1 month after
injection (a). Severe tortuosity and congestion of central retinal veins decreased gradually, and were nearly resolved at 1 year follow-up (a).
Dramatic Improvements in disc swelling, vascular changes, and severe retinal hemorrhages were noted only 1 week later the treatment, and the
favorable condition remained well until 1 year (b)
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months in the IVD-treated group (Table 2, p < 0.001),
and from 20.60 ± 15.38 at baseline to 8.24 ± 4.75 at 12
months in the observation group (Table 2, p = 0.010).
However, the improvement in retinal hemorrhage grades
was significantly larger in the treated group than in the
non-treated group (Table 2, p = 0.006). The average
numbers of cotton wool spots significantly decreased
from 3.89 ± 3.28 at baseline to 1.22 ± 0.60 at 12 months
in the IVD-treated group (Table 2, p = 0.002), and from
3.75 ± 2.79 at baseline to 1.18 ± 0.40 in the observed
group (Table 2, p = 0.004). However, changes over time
did not show significant differences between the groups
(Table 2, p = 0.42). Figure 3 shows representative images
of both groups at each time point. IVD-treated eyes had
more prominent improvements in retinal hemorrhage,
vascular tortuosity, and disc edema than in untreated
eyes.
Longitudinal changes of OCT parameters over 1 year
Peripapillary RNFL thickness decreased significantly
from 238.66 ± 39.09 μm at baseline to 144.40 ± 10.90 μm
in the IVD-treated group (Table 3, p = 0.023), though it
showed no significant change over 1 year in the observa-
tion group (Table 3, p = 0.56). It was remarkable that
IVD implant treatment caused significant improvement
in disc swelling in CRVO eyes (Table 3, p = 0.010).
When comparing RNFL thickness between the groups at
each time point, statistically significant differences were
noted at the 1- and 12-month evaluations, with the
IVD-treated group achieving significantly greater im-
provement (p < 0.001 and p = 0.009, respectively; Table 3
and Fig. 4). Central macular thickness and subfoveal
choroidal thickness revealed no significant changes dur-
ing the follow-up period in both groups (Table 3).
Changes of visual acuity and visual symptoms over 1 year
The mean BCVA changed from 0.11 ± 0.23 logMAR at
baseline to 0.02 ± 0.20 logMAR at 12months in the ob-
servation group (Wilcoxon signed-rank test, p = 0.375),
and from 0.12 ± 0.33 at baseline to 0.01 ± 0.06 logMAR
Table 2 Periodic changes in pathomorphologic findings from
fundus
Observation group IVD-treated group p-value
Mean SD Mean SD
Vascular tortuosity (μm/μm)
Superior
Baseline 0.24 0.14 0.34 0.20 0.78*
1 month 0.24 0.09 0.25 0.06 0.90*
3 months 0.21 0.08 0.20 0.07 0.98*
6 months 0.19 0.07 0.18 0.07 0.87*
12 months 0.18 0.05 0.17 0.07 0.89*
p-value 0.094† 0.025† 0.014‡
Inferior
Baseline
0.50 0.15 0.67 0.45 0.13*
1 month 0.46 0.18 0.40 0.31 0.26*
3 months 0.38 0.13 0.30 0.24 0.15*
6 months 0.34 0.12 0.30 0.30 0.59*
12 months 0.33 0.15 0.18 0.13 0.14*
p-value 0.059† 0.002† 0.036‡
Vascular width (μm)
Superior
Baseline 297.28 69.87 310.13 79.89 0.12*
1 month 288.45 68.61 266.94 71.33 0.020*
3 months 273.33 54.78 262.47 55.37 0.13*
6 months 270.71 47.81 252.53 51.64 0.39*
12 months 238.37 70.56 245.03 58.82 0.48*
p-value 0.014† 0.007† 0.024‡
Inferior
Baseline 285.30 68.63 295.05 88.79 0.13*
1 month 288.85 47.55 258.60 59.37 0.012*
3 months 250.22 49.02 236.21 50.38 0.062*
6 months 248.00 37.73 216.44 69.29 0.26*
12 months 227.01 49.21 213.20 48.21 0.22*
p-value 0.11† 0.001† 0.003‡
Retinal hemorrhage (score)
Baseline 20.60 15.38 27.70 9.70 0.052*
1 month 19.62 11.63 12.50 10.30 0.20*
3 months 12.22 8.52 8.01 9.00 0.062*
6 months 11.20 8.24 7.40 5.86 0.18*
12months 8.24 4.75 3.16 4.88 0.062*
p-value 0.010† < 0.001† 0.006‡
Cotton wool spots (number)
Baseline 3.75 2.79 3.89 3.28 0.24*
1 month 2.75 2.10 2.11 3.10 0.67*
Table 2 Periodic changes in pathomorphologic findings from
fundus (Continued)
Observation group IVD-treated group p-value
Mean SD Mean SD
3months 2.33 0.22 2.03 0.15 0.66*
6 months 2.12 0.38 2.01 0.34 0.74*
12months 1.18 0.40 1.22 0.60 0.76*
p-value 0.004† 0.002† 0.42‡
Analysis used *Mann-Whitney U test to compare groups at each time-point;
†Wilcoxon signed-rank test to compare baseline and endpoints within a group;
and ‡generalized estimating equation to compare changes with time between
the groups
IVD intravitreal dexamethasone
The bold font for P-values indicates a statistical significance (i.e., P < .05)
Choi et al. BMC Ophthalmology           (2019) 19:92 Page 6 of 11
at 12 months in the IVD-treated group (Wilcoxon
signed-rank test, p = 0.366), revealing no significant
differences between the two groups (generalized esti-
mating equation, p = 0.484). All CRVO patients with
good VA (higher than 0.20 logMAR) complained of
various visual discomforts including blurry vision,
cloudy vision, or newly developed multiple blind
spots. The symptoms from patients in the observation
group improved after 70.7 ± 27.37 days without treat-
ment, whereas IVD-treated patients showed signifi-
cantly faster improvement in visual symptoms, in
20.7 ± 18.53 days (Mann-Whitney U test, p < 0.001).
Discussion
We retrospectively compared non-ischemic CRVO with-
out ME cases to determine the effect of IVD therapy.
This study revealed for the first time that IVD-treated
CRVO eyes had greater improvement in venous en-
gorgement, as indicated by improvement in vascular pa-
rameters (e.g., tortuosity and width), and reduction of
retinal hemorrhage compared to untreated eyes. IVD
implantation was also effective in reducing disc swelling,
as a more prominent decrease in RNFL thickness was
observed in the treated group.
The natural clinical course of the two CRVO types are
considerably different: outcome is much better in
non-ischemic CRVO than in ischemic CRVO [26]. In
our study, retinal venous engorgement, venous tortuos-
ity, and optic disc edema remained after 1 year in 63.6,
54.5, and 36.3%, respectively, of observed CRVO patients
without treatment. It is remarkable that venous engorge-
ment/tortuosity was seen only in 30.0% / 22.2% of pa-
tients, respectively, and optic disc edema had resolved in
all cases of IVD-treated CRVO eyes in our study. Ac-
cording to a large-scale retrospective study, more than
12% of non-ischemic CRVO cases converted to ischemic
CRVO [23]. In our study, ischemic conversion was not
observed in both treated or untreated CRVO eyes. How-
ever, our study did not include a large enough number
of patients to demonstrate the effect of IVD on ischemic
conversion of CRVO.
Visual prognosis of CRVO has been widely reported to
be poor, most commonly caused by ME [26]. However,
even without ME, visual loss from CRVO is possible due
to macular ischemia, retinal neovascularization, or neo-
vascular glaucoma [12, 27]. CRVO patients in our study
also suffered from poor VA at initial visit or complained
of severe deterioration of vision quality, even though
their visual loss was not severe. There was no significant
difference in final VA between the IVD-treated group
and the observation group; however, symptomatic im-
provement was much faster by about 50 days and more
complete in the treated group. We expect that the treat-
ment group will be able to show a more significant im-
provement in VA than in observation group, if we
perform a study with a sufficient number of CRVO
patients.
For ME secondary to CRVO, previously published
studies show that IVD [15, 28] and anti-vascular endo-
thelial growth factor (VEGF) [27, 29–31] treatments are
Fig. 3 Representative figures of untreated (a) and Ozurdex-treated (b) central retinal vein occlusion eyes at each time point. Retinal hemorrhage
was more extensive in (b) compared to (a) at baseline. In untreated eye (a), some dot hemorrhages were still found from 6months to 12 months.
However, no additional hemorrhagic signs were observed after 6 months in Ozurdex -treated eye (b). Vessel tortuosity was dramatically improved
after 1 month in treated eye (b), while engorged vessels remained almost unchanged during the 12-month follow-up in untreated eye (a).
Edematous change in the disc was more prominent in treated eye (b), and it gradually resolved throughout the follow-up period
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effective in achieving significant improvement in BCVA.
However, there have yet not been definitively proven treat-
ments for CRVO eyes without ME. The most recent surgi-
cal treatment trials by radial optic neurotomy with pars
plana vitrectomy showed controversial results [32, 33]. The
theoretical basis for radial optic neurotomy for treatment of
CRVO was to relieve pressure at the scleral canal, an optic
nerve decompression procedure, thereby relieving ischemia
induced by compartment syndrome. Thrombolytic therap-
ies are usually advised to CRVO patients based on evidence
of their proven effectiveness in major systemic venous
thrombotic disorders. However, Hayreh [12] revealed that
improvement in vision and visual field disorder was less
likely for aspirin users. Retinal laser photocoagulation is
only indicated for neovascularization [34, 35].
The pathophysiology of CRVO is not completely
understood. It is believed to result from a blockage of
central venous outflow, commonly at the site of optic
disc or at arteriovenous crossings, and thrombosis of the
main retinal vein is thought to result in CRVO [23, 36]. In
elderly patients, venous stasis caused by arteriosclerotic
changes of retinal artery, and fibrous tissue envelope is the
predominate mechanism for occlusion [37], whereas a hy-
percoagulable status is the main cause in young patients
[38]. However, CRVOs also occurs commonly in healthy
patients with no underlying systemic disease. Inflamma-
tion and edema of ONH leading to compression of CRV
have been suggested as possible causes of CRVO [9, 16].
This may account for the favorable anatomical and func-
tional outcomes in eyes treated with IVD in our study.
IVD will act to relieve ONH swelling by providing an
anti-inflammatory effect, thereby alleviating ONH edema.
Given the paucity of data regarding the exact patho-
physiology of CRVO and its treatment, especially in
non-ischemic CRVO without ME, our treatment out-
come is encouraging. We speculate that IVD exerts its
beneficial effects by the following mechanism. Compart-
ment syndrome at the optic nerve canal could lead to
axonal and capillary compression in ONH. The resultant
pressure applied to CRV could lead to narrowing of CRV
diameter (mechanical compression of CRV) and stasis of
venous return from central retinal artery (impairment of
venous perfusion) at the lamina cribrosa level. As a re-
sult, increased ischemia and release of cytotoxic factors
could lead to vasogenic and cytotoxic disc edema, aggra-
vating the compartment syndrome and creating a vicious
cycle. This might explain the favorable response to IVD as
observed in our study. IVD could counteract both released
inflammatory factors and VEGF, thereby reducing disc
edema, which would help CRV to restore its original
diameter and improve venous return. This explains why
patients who received IVD immediately began to show
resolution of disc edema along with improvement in ret-
inal hemorrhage and venous tortuosity. These changes,
which imply pathophysiologic improvement, are clinically
meaningful in terms of lowering the risk of RVO recur-
rence and secondary complication development.
This study was limited by the small number of in-
cluded subjects and its retrospective nature. Since we
could only analyze indirect changes in impairment of
central venous return, direct measurement of venous
perfusion was not available. Through prospectively
planned studies, an analysis based on fluorescein angiog-
raphy or OCT angiography should be performed to
evaluate the change of retinal perfusion more accurately.
As VA only reflects foveal function, assessment of VA
alone seems insufficient to compare the visual function
between treated and untreated CRVO eyes. The second-
ary outcome of visual symptoms is subjective, and it
may be affected by placebo effects. To determine func-
tional improvement of IVD-treated CRVO, changes in
visual field and electroretinography should be analyzed
and compared in future prospective studies, as these
were not performed in our study.
Table 3 Longitudinal changes in parameters from spectral-
domain optical coherence tomography
Observation group IVD-treated group p-value
Mean SD Mean SD
Peripapillary RNFL thickness (μm)
Baseline 230.00 37.80 238.66 39.09 0.23*
1 month 287.00 36.59 186.00 59.90 < 0.001*
3 months 207.72 27.87 184.70 29.41 0.066*
6 months 195.25 58.65 177.42 41.20 0.062*
12months 212.33 47.92 144.40 10.90 0.009*
p-value 0.56† 0.023† 0.010‡
Central macular thickness (μm)
Baseline 224.92 36.38 225.02 67.02 0.89*
1 month 229.76 64.33 235.13 42.06 0.87*
3 months 230.10 22.06 226.30 46.50 0.60*
6 months 222.61 46.50 226.03 22.28 0.83*
12months 235.00 12.11 234.75 23.96 0.87*
p-value 0.82† 0.88† 0.52‡
Subfoveal choroidal thickness (μm)
Baseline 230.51 95.22 227.94 91.04 0.73*
1 month 246.85 35.40 244.92 76.95 0.88*
3 months 229.10 23.74 230.55 71.00 0.86*
6 months 228.06 79.16 226.84 72.89 0.91*
12months 224.51 4.30 234.30 54.72 0.66*
p-value 0.81† 0.84† 0.49‡
Analysis used *Mann-Whitney U test to compare the groups at each time-
point; †Wilcoxon signed-rank test to compare baseline and endpoints within a
group; and ‡generalized estimating equation to compare changes with time
between the groups
IVD intravitreal dexamethasone, RNFL retinal nerve fiber layer
The bold font for P-values indicates a statistical significance (i.e., P < .05)
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In summary, IVD implant injections seem to have sig-
nificant beneficial effects in the improvement of venous
engorgement, retinal hemorrhage, and disc swelling in
non-ischemic CRVO patients. The action mechanisms of
these implants for such pathomorphologic improve-
ments should be studied in more detail, as they may
provide additional evidence for treatment use. Further
study with more patients is required to reveal whether
dexamethasone implants can also provide improvement
in visual function, such as retinal sensitivity.
Conclusion
This retrospective cohort study firstly revealed that IVD
implant for the treatment of CRVO without ME was
significantly effective in improving venous engorgement,
retinal hemorrhage, RNFL swelling, and visual symptoms
by presumed alleviation of venous outflow. In two cases
treated with IVD implants, a complete resolution of cilior-
etinal artery occlusion associated with CRVO was ob-
served. Therefore, we concluded that IVD implant may be
an effective treatment option in CRVO with no ME and
further studies are warranted to verify this.
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